Influence of Anesthesia Drugs on Impedance Aggregometry

NCT ID: NCT01454427

Last Updated: 2011-10-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Impedance aggregometry (IA) (Multiplate®)is a new whole blood platelet function test with potential use in anesthesia and intensive care. Most anesthetic drugs have been shown to have in vitro antiplatelet activity. The goal of this in vitro study is to evaluate the effect of several drugs, frequently used in cardiac anesthesia and intensive care, on platelet function as measured by IA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Impedance aggregometry (IA) on the multiple platelet function analyzer (Multiplate®) ) is a whole blood point of care test evaluating platelet function. In IA, the increase in electrical impedance of whole blood is measured after the addition of a platelet activator. Some of the activators available are arachidonic acid (ASPI Test), ADP (ADP Test), TRAP-6 (TRAP Test) and collagen (COL TEST).

When an activator is added to the blood sample, the activated platelets will aggregate on the electrodes embedded in the test recipient. As platelets accumulate on the electrodes surface, the impedance will increase. The increase is measured and expressed in arbitrary units (AU). Reduced impedance implies platelet dysfunction or the presence of specific platelet inhibitors. For example, the ASPI test is inhibited in the presence of acetylsalicylic Acid and clopidrel inhibits the ADP test. Thrombin (TRAP) is an extremely potent agonist which can be used to monitor GpIIb/IIIa therapy.

The Multiplate® analyzer may have an important role in detecting and analyzing perioperative coagulopathies, but many drugs, routinely used in cardiac anesthesia or in the intensive care unit, have known in vitro antiplatelet effects, and may interfere with IA interpretation.

The goal of the study is to evaluate the influence of lidocaine, propofol, midazolam, and magnesium on the results of impedance aggregometry and to understand to which extent the tests are modified by the presence of one of these drugs.

20 healthy volunteers aged 18 to 65 years old will be recruited. Exclusion criteria are the use of non-steroidal anti-inflammatory drugs for 2 weeks prior to donation and known coagulation disorders. Whole blood is taken from the antecubital vein. Platelet count is measured. Blood samples for Multiplate® analysis are drawn in hirudin anticoagulated tubes. During storage, blood is gently moved in order to avoid sedimentation and spontaneous platelet aggregation.

For each sample baseline measurements are performed using ASPI Test, ADP Test, TRAP Test and COL Test.

The four study drugs are added to the blood samples, in isovolumic dilutions, to obtain subclinical, normal or near toxic plasma concentrations (table 1).

Study drugs low intermediate high Lidocaine (mcg/ml) 1 3 6 Magesium (mMol/l) 0.4 1 2.5 Midazolam (ng/ml) 150 250 500 Propofol (mcg/ml) 2 5 8 Table 1. Plasma concentration of the four study drugs

For every concentration, IA is measured using the 4 different activators. For every test and dose, the area under the curve is compared with the baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy volunteers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 65 years old

Exclusion Criteria

* Use of non-steroidal anti-inflammatory drugs for 2 weeks prior to donation.
* Known coagulation disorders.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Lausanne Hospitals

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carlo E Marcucci, MD

Role: PRINCIPAL_INVESTIGATOR

University of Lausanne Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Lausanne Hospitals

Lausanne, Canton of Vaud, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Morisoli AP, Gronchi F, Ferrari E, Blanc C, Frascarolo P, Angelillo-Scherrer A, Marcucci C. The influence of drugs used in cardiac anaesthesia and critical care on multiple electrode aggregometry: an in-vitro volunteer study. Eur J Anaesthesiol. 2014 Sep;31(9):499-504. doi: 10.1097/EJA.0000000000000113.

Reference Type DERIVED
PMID: 25010745 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

122/10

Identifier Type: -

Identifier Source: org_study_id